Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 4, 2011, Pages 333-339

  Van Zyl, Gert Uves ^a   Van Mens, Thijs E ^b   McIlleron, Helen ^c   Zeier, Michele ^d   Nachega, Jean B ^d,e   Decloedt, Eric ^c   Malavazzi, Carolina ^f   Smith, Peter ^c   Huang, Yong ^g   Merwe, Lize Van Der ^h,i   Gandhi, Monica ^j   Maartens, Gary ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f Medecins Sans Frontieres   (South Africa)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁱ UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

hair concentration; lopinavir; medication adherence; plasma concentration; protease inhibitor resistance mutations; resource limited settings

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HAIR LEVEL; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA;

ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HAIR; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLASMA; PYRIMIDINONES; RNA, VIRAL; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 79952440934     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820dc0cc     Document Type: Article

References (22)

1. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach. Geneva, Switzerland: WHO, 2002.
2. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006 Revision. Geneva, Switzerland: WHOm 2006.
3. Quiros-Roldan E, Airoldi M, Moretti F, et al. Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Anal. 2002;16:76-78. (Pubitemid 34293084)
4. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and crossresistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol. 2001;65: 445-448. (Pubitemid 32959067)
5. Frost SD, Nijhuis M, Schuurman R, et al. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol. 2000;74:6262-6268. (Pubitemid 30429790)
6. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22:75-82. (Pubitemid 350294880)
7. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2010 Revision. Geneva, Switzerland: WHO, 2010.
8. Mo H, King MS, King K, et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005;79:3329-3338. (Pubitemid 40330935)
9. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ ritonavirbased regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50:474-481.
10. Barreiro P, Corbaton A, Nunez M, et al. Tolerance of didanosine as enteric-coated capsules versus buffered tablets. AIDS Patient Care STDS. 2004;18:329-331. (Pubitemid 38821788)
11. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679-1687.
12. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009; 51:147-152.
13. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106. (Pubitemid 351679596)
14. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1): S79-S87. (Pubitemid 44885645)
15. Huang Y, Gandhi M, Greenblatt RM, et al. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:3401-3409.
16. Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23: 471-478.
17. Cassani M, Da Re N, Giuliani L, et al. Experience with hair testing in the clinical biochemistry laboratory of Ca' Granda Niguarda Hospital, Milan, Italy. Forensic Sci Int. 1997;84:17-24. (Pubitemid 27055619)
18. Kosuge K, Uematsu T, Araki SI, et al. Comparative dispositions of ofloxacin in human head, axillary, and pubic hairs. Antimicrob Agents Chemother. 1998;42:1298-1302. (Pubitemid 28227944)
19. van Zyl GU, Claassen M, Engelbrecht S, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol. 2008;80:942-946. (Pubitemid 351657002)
20. van Zyl GU, van der Merwe L, Claassen M, et al. Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J. 2009;28:1125-1127.
21. Pujades-Rodriguez M, Balkan S, Arnould L, et al. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304:303-312.
22. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIVantiretroviral therapy. J Antimicrob Chemother. 2004;53: 696-699. (Pubitemid 38660267)